Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Toy mirando en twitter y parece que Ziop no tiene buenas noticias ....
Ziopharm terminates development of palifosfamide
Ziopharm announced that its Phase 3 trial of palifosfamide for the treatment of metastatic soft tissue sarcoma in the first-line setting did not meet its primary endpoint of progression-free survival. The study's independent data monitoring committee has recommended that patients be followed for overall survival, the study's secondary endpoint, however the company does not expect to continue follow up for OS. Palifosfamide was well tolerated, with a safety profile in combination with doxorubicin observed in the study comparable with other palifosfamide clinical trials in soft tissue sarcoma. Full data from PICASSO 3 will be submitted for publication in a scientific journal. With this outcome, Ziopharm has made the decision to immediately place exclusive strategic focus on its synthetic biology programs, which are being developed in partnership with Intrexon Corporation.
No entiendo muy bien el texto,pero en twitter la palabra Fail salia con frecuencia!